Literature DB >> 30364516

Identifying and treating the prodromal phases of bipolar disorder and schizophrenia.

Susan Conroy1, Michael Francis1, Leslie A Hulvershorn1.   

Abstract

PURPOSE OF REVIEW: The goal of this paper is to review recent research on the identification and treatment of prodromal periods that precede bipolar and psychotic disorders. We also sought to provide information about current best clinical practices for prodromal youth. RECENT
FINDINGS: Research in the areas of identifying prodromal periods has rapidly advanced. Calculators that can predict risk are now available for use during both bipolar and psychotic disorder prodromes. Cognitive behavior therapies have emerged as the gold standard psychosocial interventions for the psychosis prodrome, while several other types of therapies hold promise for treatment during the bipolar prodrome. Due to safety and efficacy concerns, pharmacologic treatments are not currently recommended during either prodromal period.
SUMMARY: While additional research is needed to develop useful clinical tools to screen and diagnose during prodromal phases, existing literature has identified constellations of symptoms that can be reliably identified in research settings. Specialized psychotherapies are currently recommended to treat prodromal symptoms in clinical settings. They may also be useful to curtail future episodes, although further research is needed.

Entities:  

Keywords:  bipolar disorder; psychosis prodrome; schizophrenia

Year:  2018        PMID: 30364516      PMCID: PMC6196741          DOI: 10.1007/s40501-018-0138-0

Source DB:  PubMed          Journal:  Curr Treat Options Psychiatry


  79 in total

Review 1.  "A stitch in time" ... the scope for preventive strategies in early psychosis.

Authors:  P D McGorry
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1998       Impact factor: 5.270

2.  Prevalence of suicide risk factors in people at ultra-high risk of developing psychosis: a service audit.

Authors:  Paul Hutton; Samantha Bowe; Sophie Parker; Sarah Ford
Journal:  Early Interv Psychiatry       Date:  2011-11       Impact factor: 2.732

3.  Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial.

Authors:  David J Miklowitz; Kiki D Chang; Dawn O Taylor; Elizabeth L George; Manpreet K Singh; Christopher D Schneck; L Miriam Dickinson; Meghan E Howe; Judy Garber
Journal:  Bipolar Disord       Date:  2011-02       Impact factor: 6.744

4.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

5.  Symptomatology of the initial prodromal phase in schizophrenia.

Authors:  Philippos Gourzis; Aggeliki Katrivanou; Stavroula Beratis
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

6.  The ABC Schizophrenia Study: a preliminary overview of the results.

Authors:  H Häfner; K Maurer; W Löffler; W an der Heiden; P Munk-Jørgensen; M Hambrecht; A Riecher-Rössler
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1998-08       Impact factor: 4.328

Review 7.  Interventions for youth at high risk for bipolar disorder and schizophrenia.

Authors:  Robert K McNamara; Jeffrey R Strawn; Kiki D Chang; Melissa P DelBello
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2012-10

Review 8.  Intervention in individuals at ultra-high risk for psychosis: a review and future directions.

Authors:  Patrick D McGorry; Barnaby Nelson; G Paul Amminger; Andreas Bechdolf; Shona M Francey; Gregor Berger; Anita Riecher-Rössler; Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Merete Nordentoft; Ian Hickie; Philip McGuire; Michael Berk; Eric Y H Chen; Matcheri S Keshavan; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2009-06-30       Impact factor: 4.384

9.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

Authors:  Patrick D McGorry; Barnaby Nelson; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Annette Thampi; Gregor E Berger; G Paul Amminger; Magenta B Simmons; Daniel Kelly; Grad Dip; Andrew D Thompson; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

10.  First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences.

Authors:  H Häfner; A Riecher-Rössler; K Maurer; B Fätkenheuer; W Löffler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

View more
  4 in total

1.  Applying a Transdiagnostic Cognitive-Behavioral Treatment to Adolescents at High Risk for Serious Mental Illness: Rationale and Preliminary Findings.

Authors:  Marc J Weintraub; Jamie Zinberg; Carrie E Bearden; David J Miklowitz
Journal:  Cogn Behav Pract       Date:  2019-08-07

2.  Schizophrenia Outside the Brain.

Authors:  Aline Gazzola Fragnani Valença; Bradley Joseph Smith
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Neuroinflammation and neuroprogression produced by oxidative stress in euthymic bipolar patients with different onset disease times.

Authors:  Daniela Delwing-de Lima; Luiz Arthur Rangel Cyrino; Gabriela Kozuchovski Ferreira; Débora Delwing Dal Magro; Claudia Regina Calegari; Heloisi Cabral; Natalia Cavichioli; Silvia Aparecida Ramos; Oliver Matheus Ullmann; Yasmin Mayer; Luana Carla Pscheidt; Maria Augusta Schramm; Maria Cecília Tomasi; Felipe Luis Schmoller Stammerjohann; Larissa Delmonego; Maria Helena Packer; Heloiza Fiamoncini
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

4.  Risk Stratification for Bipolar Disorder Using Polygenic Risk Scores Among Young High-Risk Adults.

Authors:  Silvia Biere; Thorsten M Kranz; Silke Matura; Kristiyana Petrova; Fabian Streit; Andreas G Chiocchetti; Oliver Grimm; Murielle Brum; Natalie Brunkhorst-Kanaan; Viola Oertel; Aliaksandr Malyshau; Andrea Pfennig; Michael Bauer; Thomas G Schulze; Sarah Kittel-Schneider; Andreas Reif
Journal:  Front Psychiatry       Date:  2020-10-26       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.